These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16551782)

  • 1. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
    Hausmann R; Rettinger J; Gerevich Z; Meis S; Kassack MU; Illes P; Lambrecht G; Schmalzing G
    Mol Pharmacol; 2006 Jun; 69(6):2058-67. PubMed ID: 16551782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
    Rettinger J; Braun K; Hochmann H; Kassack MU; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
    Neuropharmacology; 2005 Mar; 48(3):461-8. PubMed ID: 15721178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
    Kassack MU; Braun K; Ganso M; Ullmann H; Nickel P; Böing B; Müller G; Lambrecht G
    Eur J Med Chem; 2004 Apr; 39(4):345-57. PubMed ID: 15072843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
    Braun K; Rettinger J; Ganso M; Kassack M; Hildebrandt C; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):285-90. PubMed ID: 11521173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
    Farmer LK; Schmid R; Evans RJ
    J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
    Hechler B; Magnenat S; Zighetti ML; Kassack MU; Ullmann H; Cazenave JP; Evans R; Cattaneo M; Gachet C
    J Pharmacol Exp Ther; 2005 Jul; 314(1):232-43. PubMed ID: 15792995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
    Suzuki E; Kessler M; Montgomery K; Arai AC
    Mol Pharmacol; 2004 Dec; 66(6):1738-47. PubMed ID: 15448189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ectodomain lysines and suramin block of P2X1 receptors.
    Sim JA; Broomhead HE; North RA
    J Biol Chem; 2008 Oct; 283(44):29841-6. PubMed ID: 18765669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of functional P2X(1) receptors in mouse megakaryocytes.
    Ikeda M
    Thromb Res; 2007; 119(3):343-53. PubMed ID: 16626790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF449, a novel picomolar potency antagonist at human P2X1 receptors.
    Hülsmann M; Nickel P; Kassack M; Schmalzing G; Lambrecht G; Markwardt F
    Eur J Pharmacol; 2003 May; 470(1-2):1-7. PubMed ID: 12787824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
    Ullmann H; Meis S; Hongwiset D; Marzian C; Wiese M; Nickel P; Communi D; Boeynaems JM; Wolf C; Hausmann R; Schmalzing G; Kassack MU
    J Med Chem; 2005 Nov; 48(22):7040-8. PubMed ID: 16250663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
    Meis S; Hamacher A; Hongwiset D; Marzian C; Wiese M; Eckstein N; Royer HD; Communi D; Boeynaems JM; Hausmann R; Schmalzing G; Kassack MU
    J Pharmacol Exp Ther; 2010 Jan; 332(1):238-47. PubMed ID: 19815812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.
    Rettinger J; Schmalzing G; Damer S; Müller G; Nickel P; Lambrecht G
    Neuropharmacology; 2000 Aug; 39(11):2044-53. PubMed ID: 10963748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
    Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.
    Soto F; Lambrecht G; Nickel P; Stühmer W; Busch AE
    Neuropharmacology; 1999 Jan; 38(1):141-9. PubMed ID: 10193905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of P2X3-receptors present in neurones of the rat dorsal root ganglia.
    Rae MG; Rowan EG; Kennedy C
    Br J Pharmacol; 1998 May; 124(1):176-80. PubMed ID: 9630357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord.
    Heinrich A; Kittel A; Csölle C; Sylvester Vizi E; Sperlágh B
    Neuropharmacology; 2008 Feb; 54(2):375-86. PubMed ID: 18063000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suramin analogues as subtype-selective G protein inhibitors.
    Freissmuth M; Boehm S; Beindl W; Nickel P; Ijzerman AP; Hohenegger M; Nanoff C
    Mol Pharmacol; 1996 Apr; 49(4):602-11. PubMed ID: 8609887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices.
    Papp L; Balázsa T; Köfalvi A; Erdélyi F; Szabó G; Vizi ES; Sperlágh B
    J Pharmacol Exp Ther; 2004 Sep; 310(3):973-80. PubMed ID: 15084650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking.
    Wolf C; Rosefort C; Fallah G; Kassack MU; Hamacher A; Bodnar M; Wang H; Illes P; Kless A; Bahrenberg G; Schmalzing G; Hausmann R
    Mol Pharmacol; 2011 Apr; 79(4):649-61. PubMed ID: 21191044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.